1
|
Zeng B, Li J, Wang Y, Chen P, Wang X, Cui J, Liu L, Hu X, Cao Q, Xiao Y, Dong J, Sun Y, Zhou Y. In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus Candida albicans. Oncotarget 2017; 8:69972-69982. [PMID: 29050256 PMCID: PMC5642531 DOI: 10.18632/oncotarget.19542] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 06/19/2017] [Indexed: 11/25/2022] Open
Abstract
As the most frequent fungal pathogen in humans, Candida albicans can develop serious drug resistance because its biofilms are resistant to most antifungal agents; this leads to an urgent need to develop novel antifungals. Here, we evaluated the efficacy of an antithrombotic drug, suloctidil, against C. albicans biofilms in vitro and in vivo. We found that suloctidil is effective to inhibit C. albicans biofilm, with a minimum inhibitory concentration (MIC80) of 4 μg/mL, a biofilm inhibiting concentration (BIC80) of 16 μg/mL and a biofilm eradicating concentration (BEC80) of 64 μg/mL. Furthermore, the concentration-dependent characteristics of suloctidil were shown by its time-kill curves. Scanning electron microscopy images clearly revealed the morphological effects of suloctidil on biofilm. Yeast-to-hyphal form switching is a key virulence factor of C. albicans; therefore, we performed hyphal growth tests and observed that suloctidil inhibited yeast-to-hyphal form switching. This result was consistent with the down-regulation of hypha-specific gene (HWP1, ALS3, and ECE1) expression levels after suloctidil treatment. In vivo, 256 μg/mL of suloctidil significantly reduced fungal counts (P<0.01) compared to that in groups without treatment; the treatment group induced a slight histological reaction, especially when the treatment lasted for 5 days (P<0.01). Taken together, our data suggest that suloctidil is a potential antifungal agent.
Collapse
Affiliation(s)
- Beini Zeng
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Jiachen Li
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Yajie Wang
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Pengxiang Chen
- Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Xiaohong Wang
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Jianfeng Cui
- Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Lidong Liu
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Xiaoyan Hu
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Qian Cao
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Ying Xiao
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Junlu Dong
- Department of Neurobiology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Yundong Sun
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| | - Yabin Zhou
- Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China
| |
Collapse
|
2
|
Higo K, Karasawa A. Effects of a thromboxane A2-receptor antagonist, a thromboxane synthetase inhibitor and aspirin on prostaglandin I2 production in endothelium-intact and -injured aorta of guinea pigs. JAPANESE JOURNAL OF PHARMACOLOGY 1994; 66:471-9. [PMID: 7723224 DOI: 10.1254/jjp.66.471] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We examined the effects of KW-3635, a thromboxane (TX) A2-receptor antagonist, and OKY-046, a TX synthetase inhibitor, on the prostaglandin (PG) I2 production in endothelium-intact and -injured guinea pig aorta and compared them with those of aspirin. In the endothelium-intact aorta, both the low (3 mg/kg) and the high (100 mg/kg) dose of aspirin similarly reduced the PGI2 production, as measured ex vivo 1 hr after the injury. In contrast, neither KW-3635 (10 mg/kg) nor OKY-046 (30 mg/kg) inhibited the PGI2 production. The endothelial injury, induced by balloon catheterization, caused a reduction of PGI2 production in the aorta and decline of plasma PGI2/TXA2 ratio. In the endothelium-injured animals, the high dose of aspirin further reduced the PGI2 production in the aorta, whereas KW-3635 and OKY-046 did not affect it. KW-3635 and OKY-046 also ameliorated the reduced ratio of PGI2/TXA2 in the plasma. The present results demonstrate that aspirin, but not KW-3635 or OKY-046, reduces the PGI2 production in the aorta either in the endothelium-intact or -injured state. It is thus suggested that the TXA2-receptor antagonist and the TX synthetase inhibitor have some advantages over aspirin when used for the prevention of acute thrombosis after percutaneous transluminal angioplasty.
Collapse
Affiliation(s)
- K Higo
- Department of Pharmacology, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan
| | | |
Collapse
|
3
|
De Paermentier F, Heuschling P, Knoops B, Janssens De Varebeke P, Pauwels G, Laszlo De Kaszon-Jakabfalva C, Van den Bosch De Aguilar P. Suloctidil increases the rat brain cortex microvascular regeneration after a lesion. Life Sci 1989; 44:41-7. [PMID: 2464117 DOI: 10.1016/0024-3205(89)90216-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A "cavity" lesion made by aspiration in the rat occipital cortex induces a parenchymal and a vascular reaction in its vicinity. The first was mainly characterized by cellular necrosis and gliosis, the second by an increase of the vascular network. In vehicle treated rats, a 50% significant increase of the vascular network was observed around the cavity 4 days after the lesion, in comparison to the uninjured contralateral cortex. The effects of a vasoactive substance, suloctidil, on the vascular reaction was studied in the brain cortex. A single oral dose of suloctidil (30 mg/kg; 2 hours before the sacrifice) gave the same effect as the vehicle group. After 8 days of suloctidil oral administration (30 mg/kg; twice daily: 4 days before lesion and 4 days after) a significant increase (123%) of the vascular network was observed around the cavity. The hypothetical ways by which a chronic treatment of suloctidil induces this increase of the neovascularization observed after cortical lesion are discussed.
Collapse
Affiliation(s)
- F De Paermentier
- Laboratoire de Biologie Cellulaire, Université Catholique de Louvain, Belgium
| | | | | | | | | | | | | |
Collapse
|
4
|
Boeynaems JM, Demolle D, Van Coevorden A. Stimulation of vascular prostacyclin by SKF 525-A (proadifen) and related compounds. Biochem Pharmacol 1987; 36:1637-43. [PMID: 3109426 DOI: 10.1016/0006-2952(87)90048-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
SKF 525-A (proadifen), a well-known inhibitor of drug metabolism and cytochrome P-450 activity, stimulated the release of prostacyclin (PGI2) from the rabbit aorta in vitro. The threshold concentration producing a detectable effect was 20 microM; the time course of SKF 525-A action exhibited particular features--progressive onset, long duration and slow reversibility--distinct from those of other stimuli (ADP, ionophore A23187 f.i.). The PGI2-stimulating activity of SKF 525-A was characterized by specific structural requirements: activity was abolished by the deletion of the terminal propyl group and increased by its elongation into an isobutyl group; chlorination of the phenyl groups increased the potency. SKF 525-A increased the production of PGI2 by cultured endothelial cells from bovine aorta and human umbilical vein, but had no effect on cultured smooth muscle from the bovine aortic media. Stimulation of PGI2 release could be explained by an increased availability of free arachidonic acid, which was probably independent from cytochrome P-450 inhibition. In human platelets, SKF 525-A inhibited prostaglandin and thromboxane production induced by A23187, thrombin and ADP. Simultaneous stimulation of endothelial PGI2 and inhibition of platelet TxA2 represents an original pharmacological profile: SKF 525-A might thus constitute the prototype of a new class of antiplatelet drugs.
Collapse
|